Literature DB >> 3410802

Pharmacokinetics of cefixime in the young and elderly.

R D Faulkner1, W Bohaychuk, R A Lanc, J D Haynes, R E Desjardins, A Yacobi, B M Silber.   

Abstract

The pharmacokinetics of cefixime were compared in 12 young and 12 elderly subjects receiving 400 mg once-a-day for five days. Mean peak serum concentrations (Cmax) on days one and five in the elderly (4.90 and 5.68 mg/l) were comparable (P greater than 0.05) to those in the young subjects (3.88 and 4.74 mg/l). Serum area under the curve (AUC) values on days one and five in the elderly (41.0 and 49.5 mg.h/l) were higher (P less than 0.05) than those in young subjects (28.6 and 34.9 mg.h/l). In addition, the elimination half-life, mean residence time, average concentration, minimal concentration and renal clearance (Clr) values were significantly higher (P less than 0.05) in the elderly. A significant linear correlation (P less than 0.05) was found between the Clr of cefixime (total and unbound) and creatinine clearance. The urinary recovery (Ae0----24) and protein binding of cefixime on days one and five was similar in the elderly and young. Overall, there is no need for any dosage adjustment of the drug in the elderly.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3410802     DOI: 10.1093/jac/21.6.787

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.

Authors:  H Lode; C Müller; K Borner; C E Nord; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  Cost-effectiveness and value of an IV switch.

Authors:  P Jewesson
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

3.  Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly.

Authors:  Felix Stader; Hannah Kinvig; Melissa A Penny; Manuel Battegay; Marco Siccardi; Catia Marzolini
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

Review 4.  Considerations in dosage selection for third generation cephalosporins.

Authors:  J H Yuk-Choi; C H Nightingale; T W Williams
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

5.  An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.

Authors:  C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

Review 6.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

7.  Cefixime penetration in human renal parenchyma.

Authors:  A Leroy; B Oser; P Grise; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

Review 8.  Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential.

Authors:  R N Brogden; D M Campoli-Richards
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage.

Authors:  B R Meyers; P Wilkinson
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

10.  Relationship between renal function and disposition of oral cefixime.

Authors:  M Dhib; B Moulin; A Leroy; B Hameau; M Godin; R Johannides; J P Fillastre
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.